Inflammatory bowel disease in pregnancy
IBD pregnancy · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Active IBD, not its drugs, poses the greatest risk to pregnancy; most maintenance therapies are continued. The guiding principle is to conceive and remain in remission on safe, effective therapy.
Red flags
- Flare with rectal bleeding/systemic upset
- Dehydration or weight loss
- Features of acute severe colitis
- Deranged LFTs (consider obstetric causes)
Assessment
Differential diagnosis
- IBD flare vs pregnancy-related GI symptoms
- Hyperemesis gravidarum
- Infective gastroenteritis / C. difficile
- Pre-eclampsia (if deranged LFTs)
- Intrahepatic cholestasis of pregnancy
Investigations
- Faecal calprotectin (non-invasive flare assessment)
- FBC, CRP, albumin, ferritin, B12, folate
- Flexible sigmoidoscopy if essential (safe in pregnancy)
- MRI without gadolinium if cross-sectional imaging needed (avoid CT)
- Routine antenatal screening and nutritional review
Management
- Ideally plan conception during steroid-free remission with optimised therapy
- Continue maintenance 5-ASA, thiopurines, anti-TNF and vedolizumab/ustekinumab — the priority is sustained remission
- Stop methotrexate well before conception (teratogenic) and switch to a compatible agent
- Avoid tofacitinib and other JAK inhibitors; counsel on alternative therapy before conception
- Continue folic acid and treat/prevent iron and B12 deficiency
- Treat flares promptly — steroids and biologics are preferable to uncontrolled disease
- Time the last anti-TNF dose in the third trimester per specialist advice to reduce neonatal drug levels
- Avoid live vaccines in infants exposed to biologics in utero until ~6–12 months
- Coordinate delivery planning — active perianal Crohn's or ileoanal pouch may favour caesarean
- Maintain MDT care (gastroenterology, obstetrics, neonatology) throughout
- Continue therapy postnatally; most agents are compatible with breastfeeding
Drugs & doses
Mesalazine 2–4.8 g PO daily (continue)
Azathioprine 2–2.5 mg/kg PO once daily (continue)
Infliximab/adalimumab (continue; time third-trimester dosing)
Prednisolone 40 mg PO once daily tapering (flare)
Folic acid 5 mg PO once daily
Disposition
Joint gastroenterology-obstetric MDT; pre-conception counselling clinic.
Complications & pitfalls
- Flare causing miscarriage, preterm birth, low birth weight
- Venous thromboembolism (pregnancy plus active IBD)
- Nutritional deficiency
- Neonatal immunosuppression from in-utero biologic exposure
Exam pearls
- Active disease is more dangerous to the pregnancy than the medications used to control it
- Stop only methotrexate and JAK inhibitors; continue thiopurines and biologics
- Live vaccines (e.g. rotavirus, BCG) are contraindicated in biologic-exposed infants in the first months
- VTE risk is high — ensure thromboprophylaxis during flares and admissions
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.